TrialInternational urology and nephrology2023

Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial.

Hany Hammad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.